Literature DB >> 16528534

Causes of fever in cancer patients (prospective study over 477 episodes).

E Toussaint1, E Bahel-Ball, M Vekemans, A Georgala, L Al-Hakak, M Paesmans, M Aoun.   

Abstract

GOALS OF WORK: The aim of this study was to determine the causes of fever among cancer patients.
METHODS: All febrile cancer patients were followed up prospectively. Clinical, microbiological and radiological documentations were performed. Aetiologies of fever, type of tumour, site of infection, type of microorganism and outcome were assessed and compared between neutropenics and non-neutropenics.
RESULTS: Four hundred and seventy-seven episodes were evaluated. Infection, non-infectious causes and fever of unknown origin represented 67, 23 and 10%, respectively. The respiratory tract is the most frequently involved site in infection (29%), and in microbiologically documented infections, Gram-negative bacilli were predominant. The tumour itself (27%) or an invasive procedure (17%) were the main causes of non-infectious febrile episodes. Mortality from infection was higher among non-neutropenic (11.1%) than neutropenic patients (4.3%).
CONCLUSION: Fever in cancer patients remains a challenge, and the differentiation between infectious and non-infectious causes at onset of fever is very difficult. Despite all the prophylactic measures, infection is still the principal cause. However, the infection-related mortality is low either in neutropenic or non-neutropenic patients.

Entities:  

Mesh:

Year:  2006        PMID: 16528534     DOI: 10.1007/s00520-005-0898-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  26 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  [Flexible bronchoscopy in children. Experience at French centers of pediatric pneumology].

Authors:  P Le Roux; J de Blic; M Albertini; G Bellon; G Body; F Brémont; B Caurier; F Chomienne; F Counil; L Dalphin; V David; C Delacourt; E Deneuville; J Derelle; A Deschildre; L Donato; J C Dubus; M Fayon; J Garcia; L Heuzé; A Houzel; J Just; A Labbé; D Lesbros; C Mahraoui; A Malfroot; C Marguet; P Monrigal; J C Pautard; I Pin; I Rayet; A Sardet; M Scalbert; D Siret; C Troadec
Journal:  Rev Mal Respir       Date:  2004-12       Impact factor: 0.622

Review 3.  Fever.

Authors:  C A Dinarello; P A Bunn
Journal:  Semin Oncol       Date:  1997-06       Impact factor: 4.929

4.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Percutaneous litholapaxy. Indications and limitations of the technique in complex nephrolithiasis.

Authors:  T Schärfe; P Alken; S T Müller; C Jurincic; R Hohenfellner
Journal:  Arch Esp Urol       Date:  1990-04       Impact factor: 0.436

6.  Fever of unexplained origin in patients with cancer.

Authors:  J Klastersky; D Weerts; C Hensgens; L Debusscher
Journal:  Eur J Cancer       Date:  1973-09       Impact factor: 9.162

7.  Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

Authors:  A Cometta; W V Kern; R De Bock; M Paesmans; M Vandenbergh; F Crokaert; D Engelhard; O Marchetti; H Akan; A Skoutelis; V Korten; M Vandercam; H Gaya; A Padmos; J Klastersky; S Zinner; M P Glauser; T Calandra; C Viscoli
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

Review 8.  Science and pragmatism in the treatment and prevention of neutropenic infection.

Authors:  J Klastersky
Journal:  J Antimicrob Chemother       Date:  1998-06       Impact factor: 5.790

9.  Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis.

Authors:  A Mulabecirovic; P Gaulhofer; H W Auner; H Popper; R Krause; C Hesse; H Sill
Journal:  Ann Hematol       Date:  2004-05-05       Impact factor: 3.673

10.  Frequency and yield of postoperative fever evaluation.

Authors:  J Fanning; R A Neuhoff; J E Brewer; T Castaneda; M P Marcotte; R L Jacobson
Journal:  Infect Dis Obstet Gynecol       Date:  1998
View more
  17 in total

1.  Biomarker candidates for the detection of an infectious etiology of febrile neutropenia.

Authors:  Martin E Richter; Sophie Neugebauer; Falco Engelmann; Stefan Hagel; Katrin Ludewig; Paul La Rosée; Herbert G Sayer; Andreas Hochhaus; Marie von Lilienfeld-Toal; Tom Bretschneider; Christine Pausch; Christoph Engel; Frank M Brunkhorst; Michael Kiehntopf
Journal:  Infection       Date:  2015-08-15       Impact factor: 3.553

Review 2.  Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia.

Authors:  Caterina Fontanella; Silvia Bolzonello; Bianca Lederer; Giuseppe Aprile
Journal:  Breast Care (Basel)       Date:  2014-04       Impact factor: 2.860

3.  Neoplastic fever in patients with bone and soft tissue sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Takao Matsubara; Kunihiro Asanuma; Akihiro Sudo
Journal:  Mol Clin Oncol       Date:  2016-09-21

4.  Skin and soft tissue infections in patients with solid tumours.

Authors:  Diamantis P Kofteridis; Antonios Valachis; Eirini Koutsounaki; Sofia Maraki; Eleni Mavrogeni; Foteini N Economidou; Dimitra Dimopoulou; Kostas Kalbakis; Vassilis Georgoulias; George Samonis
Journal:  ScientificWorldJournal       Date:  2012-02-01

5.  Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.

Authors:  Rima Moghnieh; Nour Estaitieh; Anas Mugharbil; Tamima Jisr; Dania I Abdallah; Fouad Ziade; Loubna Sinno; Ahmad Ibrahim
Journal:  Front Cell Infect Microbiol       Date:  2015-02-12       Impact factor: 5.293

Review 6.  The pathophysiological basis and consequences of fever.

Authors:  Edward James Walter; Sameer Hanna-Jumma; Mike Carraretto; Lui Forni
Journal:  Crit Care       Date:  2016-07-14       Impact factor: 9.097

Review 7.  Pancreatic carcinoma masked as fever of unknown origin: A case report and comprehensive review of literature.

Authors:  Ning Shi; Cheng Xing; Xiaoyan Chang; Menghua Dai; Yupei Zhao
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Prognostic value of inflammation-based scores in patients with osteosarcoma.

Authors:  Bangjian Liu; Yujing Huang; Yuanjue Sun; Jianjun Zhang; Yang Yao; Zan Shen; Dongxi Xiang; Aina He
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting.

Authors:  Ali Hakan Kaya; Emre Tekgündüz; Fazilet Duygu; Dicle Koca; Filiz Bekdemir; Hikmetullah Batgi; Bahar Ulu Uncu; Tuğçe Nur Yiğenoğlu; Mehmet Sinan Dal; Merih Çakar Kızıl; Fevzi Altuntaş
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

10.  Comprehensive detection of pathogens in immunocompromised children with bloodstream infections by next-generation sequencing.

Authors:  Kazuhiro Horiba; Jun-Ichi Kawada; Yusuke Okuno; Nobuyuki Tetsuka; Takako Suzuki; Shotaro Ando; Yasuko Kamiya; Yuka Torii; Tetsuya Yagi; Yoshiyuki Takahashi; Yoshinori Ito
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.